medigraphic.com
ISSN 0185-3325 (Print)
Órgano Oficial del Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz

2015, Number 1

<< Back Next >>

Salud Mental 2015; 38 (1)

Síntomas residuales de la depresión: terapias coadyuvantes

Flores GEO, Terán CVA, González OJJ

Language: Spanish
References: 45
Page: 67-75
PDF size: 294.90 Kb.


ABSTRACT

Residual symptoms of depression (SRD) are those that persist despite a good response to antidepressant drug treatment. They have a high incidence in the psychiatric clinic and are significantly related to a high risk of relapse/recurrence. There are insufficient controlled studies to define a pharmacological treatment for the management of SRD, however, different long-term schemes have proven, nevertheless, that side effects involve a significant limitation. The aim of this review is to investigate and analyze the non-pharmacological treatment options for the management of the SRD. Only four type treatments were found: Cognitive Behavioral Therapy, Well-being Therapy, Mindfulness- Based Cognitive Therapy and Euthymic Therapy. The mentioned psychotherapeutic treatments reported decreased rates in relapse and/or clinimetric decreased in SRD levels


REFERENCES

  1. Wagner FA, González-Forteza C, Sánchez-García S, García-Peña C et al. Enfocando la depresión como problema de salud pública en México. Salud Mental 2012;35(1):3-11.

  2. McIntyre RS, O´Donovan C. The human cost of not achieving full remission in depression. Can J Psychiatry 2004;49(1):10s-16s.

  3. Casquero RR, Benítez MJM, Manzanera ER, Mínguez VJC et al. Guía de buena práctica clínica en depresión y ansiedad generalizada con presentación de síntomas somáticos. Madrid: Ed. Organización Médica Colegial de España; 2012.

  4. Bousoño GM, Camacho LM, Pérez PJF. Síntomas residuales y remisión en la depresión: una encuesta de opinión entre psiquiatras españoles. Psiquiatr Biol 2007;14(3):85-91.

  5. Tranter R, O´Donovan C, Chandarana P, Kennedy S. Prevalence and outcome of partial remission in depression. J Psychiatry Neurosci 2002;27(4):241-247.

  6. Zajecka JM. Treating depression to remission. J Clin Psychiatry 2003;64(15):7-12.

  7. Romera I, Pérez V, Ciudad A, Caballero L et al. Residual symptoms and functioning in depression, does the type of residual symptom matter? A post-hoc analysis. BMC Psychiatry 2013;13(51):1-7. doi:10.1186/1471- 244X-13-51.

  8. Enns MW, Swenson JR, McIntyre RS, Swinson RP et al. Clinical guidelines for the treatment of depressive disorders VII comorbidity. Can J Psychiatry 2001;46(1):77s-90s.

  9. Goldberg RJ, Steury S. Depression in the Workplace: Costs and Barriers to treatment. Psychiatr Serv 2001;52(12):1639-1643. doi:10.1176/ appi.ps.52.12.1639.

  10. Kessler RC, Barber C, Birnbaum HG, Frank RG et al. Depression in the workplace: Effects on short-term disability. Health Aff 1999;18(5):163- 171. doi:10.1377/hlthaff.18.5.163.

  11. Druss BG, Schlesinger M, Allen HM. Depressive symptoms, satisfaction with health care, and 2-year work outcomes in an employed population. Am J Psychiatry 2001;158:731-734.

  12. Lara-Muñoz MC, Robles-García R, Orozco R, Real T et al. Estudio de costo-efectividad del tratamiento de la depresión en México. Salud Mental 2010;33(4):301-308.

  13. Sobocki P, Ekman M, Agren H, Runeson B et al. The mission is remission: health economic consequences of achieving full remission with antidepressant treatment for depression. Int J Clin Pract 2006;60(7):791-798.

  14. Israel JA. The impact of residual symptoms in major depression. Pharmaceuticals 2010;3:2426-2440. ISSN 1424-8247. doi:10.3390/ph3082426.

  15. Taylor DJ, Walters HM, Vittengl JR, Krebaum S et al. Which depressive symptoms remain after response to cognitive therapy of depression and predict relapse and recurrence? J Affect Disord 2010;123(1-3):181- 187. doi:10.1016/j.jad.2009.08.007.

  16. Paykel ES, Scott J, Teasdale JD, Johnson AL et al. Prevention of relapse in residual depression by cognitive therapy. Arch Gen Psychiatry 1999;56:829-835.

  17. Karp JF, Buysse, DJ, Houck PR, Cherry C et al. Relationship of variability in residual symptoms with recurrence of major depressive disorder during maintenance treatment. Am J Psychiatry 2004;161:1877-1884.

  18. Paykel ES. Residual symptoms and relapse in depression. Medicographia 2009;31(2):157-163.

  19. Menza M, Marin H, Sokol OR. Residual symptoms in depression: Can treatment be symptom-specific? J Clin Psychiatry 2003;64(5):516-523.

  20. Galván P, Fernández E, Fonseca J. Síntomas residuales en el anciano con depresión. Semergen 2012;38(5):285-291. doi:10.1016/ j.semerg.2011.08.006.

  21. Silva H. Nuevas perspectivas en la biología de la depresión. Rev chil neuro-psiquiatr [online] 2002;40(1):9-20. ISSN 0717-9227. doi:10.4067/ S0717-92272002000500002.

  22. Ogrodniczuk JS, Piper WE, Joyce AS. Residual symptoms in depressed patients who successfully respond to short-term psychotherapy. J Affect Disord 2004;82(3):469-473.

  23. Nierenberg AA, Keefe BR, Leslie VC, Alpert JE et al. Residual symptoms in depressed patients who respond acutely to fluoxetine. J Clin Psychiatry 1999;60(4):221-225.

  24. Nierenberg AA, Husain MM, Trivedi MH, Fava M et al. Residual symptoms after remission of major depressive disorder with citalopram and risk of relapse: a STAR*D report. Psychol Med 2010;40(1):41- 50. doi:10.1017/S0033291709006011.

  25. Iovieno N, Van Nieuwenhuizen A, Clain A, Baer L et al. Residual symptoms after remission of major depressive disorder with fluoxetina and risk of relapse. Depress Anxiety 2011;28(2):137-144. doi:10.1002/ da.20768.

  26. Gastó C, Navarro V, Catalán R, Portella MJ et al. Residual symptoms in elderly major depression remitters. Acta Psychiatr Scand 2003;108(1):15-19. doi:10.1034/j.1600-0447.2003.00068.x.

  27. Dombrovski AY, Mulsant BH, Houck PR, Mazumdar S, Lenze EJ, Andreescu C, Cyranowski JM, Reynolds CF. Residual symptoms and recurrence during maintenance treatment of late-life depression. J Affect Disord 2007;103(1-3):77-82. doi:10.1016/j.jad.2007.01.020.

  28. Vieta E, Sánchez-Moreno J, Lahuerta J, Zaragoza S. Subsyndromal depressive symptoms in patients with bipolar and unipolar disorder during clinical remission. J Affect Disord 2008;107(1-3):169-174.

  29. Yang H, Chuzi S, Sinicropi-Yao L, Johnson D et al. Type of residual symptom and risk of relapse during the continuation/maintenance phase treatment of major depressive disorder with the selective serotonin reuptake inhibitor fluoxetine. Eur Arch Psychiatry Clin Neurosci 2010;260(2):145-150. doi:10.1007/s00406-009-0031-3.

  30. Nelson JC, Portera L, Leon AC. Residual symptoms in depressed patients after treatment with fluoxetine or reboxetine. J Clin Psychiatry 2005;66(11):1409-1414.

  31. McIntyre RS, Konarski JZ, Soczynska JK, Kennedy SH. Residual anxiety symptoms in depressed primary care patients. J Psychiatr Pract 2007;13(2):125-128.

  32. Nierenberg AA, Petersen TJ, Alpert JE. Prevention of relapse and recurrence in depression: The role of long-term pharmacotherapy and psychotherapy. J Clin Psychiatry 2003;64(15):13-17.

  33. Karasu TB, Gelenberg A, Merriam A, Wang P. Guía clínica para el tratamiento del trastorno depresivo mayor. Segunda edición. En: American Psychiatric Association (ed). Guías clínicas para el tratamiento de los trastornos psiquiátricos: Compendio 2006. Barcelona: Ars Medica; 2006.

  34. Madueño CAJ, Arbesú PJA, Gonçalves EF, Pérez SV et al. Guía de buena práctica clínica en algoritmos de decisión en depresión. Madrid: Ed. Organización Médica Colegial de España; 2011.

  35. Petersen TJ. Enhancing the efficacy of antidepressants with psychotherapy. J Psychopharmacol 2006;20(3):19-28.

  36. American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder. 3rd Ed. Washington: American Psychiatric Association Publishing Inc; 2010.

  37. Fava GA, Grandi S, Zielezny M, Rafanelli C et al. Four-year outcome for cognitive behavioral treatment of residual symptoms in major depression. Am J Psychiatry 1996;153(7):945-947.

  38. Scott J, Teasdale JD, Paykel ES, Johnson AL et al. Effects of cognitive therapy on psychological symptoms and social functioning in residual depression. Br J Psychiatry 2000;177:440-446.

  39. Perlis RH, Nierenberg AA, Alpert JE, Pava J et al. Effects of adding cognitive therapy to fluoxetine dose increase on risk of relapse and residual depressive symptoms in continuation treatment of major depressive disorder. J Clin Psychopharmacol 2002;22(5):474-480.

  40. Fava GA, Rafanelli C, Grandi S, Conti S et al. Prevention of recurrent depression with cognitive behavioral therapy: preliminary findings. Arch Gen Psychiatry 1998;55(9):816-820.

  41. Piet J, Hougaard E. The effect of mindfulness-based cognitive therapy for prevention of relapse in recurrent major depressive disorder: A systematic review and meta-analysis. Clin Psychol Rev 2011;31(6):1032-1040.

  42. Teasdale JD, Segal ZV, Williams JMG, Ridgeway VA et al. Prevention of relapse/recurrence in major depression by mindfulness-based cognitive therapy. J Consult Clin Psychol 2000;68(4):615-623.

  43. Ma SH, Teasdale JD. Mindfulness-based cognitive therapy for depression: Replication and exploration of differential relapse prevention effects. J Consult Clin Psychol 2004;72(1):31-40. doi:10.1037/0022- 006X.72.1.31.

  44. Kingston T, Dooley B, Bates A, Lawlor E et al. Mindfulness-based cognitive therapy for residual depressive symptoms. Psychol Psychother 2007;80(2):193-203. doi:10.1348/147608306X116016.

  45. Kiermeir J, Gassner LM, Siebörger A, Wiethoff K et al. Euthymic therapy to reduce residual symptoms of depression and strengthen self-care a randomised controlled trial. German J Psychiatry 2012;15(1):15-22.




2020     |     www.medigraphic.com